252 related articles for article (PubMed ID: 35838647)
41. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
42. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
[TBL] [Abstract][Full Text] [Related]
43. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
He J; Su C; Liang W; Xu S; Wu L; Fu X; Zhang X; Ge D; Chen Q; Mao W; Xu L; Chen C; Hu B; Shao G; Hu J; Zhao J; Liu X; Liu Z; Wang Z; Xiao Z; Gong T; Lin W; Li X; Ye F; Liu Y; Ma H; Huang Y; Zhou J; Wang Z; Fu J; Ding L; Mao L; Zhou C
Lancet Respir Med; 2021 Sep; 9(9):1021-1029. PubMed ID: 34280355
[TBL] [Abstract][Full Text] [Related]
44. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
[TBL] [Abstract][Full Text] [Related]
45. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
46. Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T; Sakai K; Kenmotsu H; Yoh K; Daga H; Ohira T; Ueno T; Aoki T; Hayashi H; Yamazaki K; Hosomi Y; Chen-Yoshikawa TF; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Inokawa H; Yamamoto N; Nishio K; Tsuboi M
Cancer Sci; 2022 Jan; 113(1):287-296. PubMed ID: 34689382
[TBL] [Abstract][Full Text] [Related]
47. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
48. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
49. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
50. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
Woodard GA; Kratz JR; Haro G; Gubens MA; Blakely CM; Jones KD; Mann MJ; Jablons DM
Clin Lung Cancer; 2021 Nov; 22(6):587-595. PubMed ID: 34544620
[TBL] [Abstract][Full Text] [Related]
51. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
Lee JS; Kim EK; Kim KA; Shim HS
Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
[TBL] [Abstract][Full Text] [Related]
52. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.
Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
Clin Lung Cancer; 2016 Sep; 17(5):e31-e43. PubMed ID: 26992846
[TBL] [Abstract][Full Text] [Related]
54. When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan.
Chen CL; Wang ST; Liao WC; Chen CH; Tu CY; Chen HJ; Hsia TC; Cheng WC
BMC Cancer; 2022 May; 22(1):571. PubMed ID: 35599308
[TBL] [Abstract][Full Text] [Related]
55. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
[TBL] [Abstract][Full Text] [Related]
56. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
57. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
Yang WJ; Gao YB; Qiu T; Wang YG; He J
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015
[No Abstract] [Full Text] [Related]
58. Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected
Li M; Hou X; Lin S; Zheng L; Liang J; Chen J; Wang N; Zhang B; Chen L
Future Oncol; 2022 Mar; 18(9):1159-1169. PubMed ID: 35109665
[TBL] [Abstract][Full Text] [Related]
59. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
60. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III
Neal JW; Costa DB; Muzikansky A; Shrager JB; Lanuti M; Huang J; Ramachandran KJ; Rangachari D; Huberman MS; Piotrowska Z; Kris MG; Azzoli CG; Sequist LV; Chaft JE
JCO Precis Oncol; 2021 Jan; 5():325-332. PubMed ID: 34151132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
